NCT06604949View on ClinicalTrials.gov

A Study of Single Dose of LP-003 in Healthy Adult Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

LP-003 200mg

Subcutaneous injection of 200 mg LP-003

DRUG

Placebo

Subcutaneous injection of placebo

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Longbio Pharma

INDUSTRY